UK Post EBMT Update Day: New data presented on haematopoietic stem cell transplantation using Treosulfan- based conditioning regimen
ConclusionThe reduced toxicity of the new treosulfan/fludarabine-based regimen makes myeloablative conditioning an option for a broad range of adults and children that were not suitable for this treatment before now (AML and MDS, as well as for additional malignant and non-malignant diseases).The clinical outcome shown in this presentation highlights that the treosulfan conditioning regimen in combination with fludarabine has the potential to become the new standard regimen for conditioning prior to allogeneic HSCT.
About medac Pharmamedac Pharma is part of medac GmbH, a privately held, multi-national pharmaceutical company with a growing pharmaceutical and diagnostics business. Founded in Germany in 1970, medac specialises in the treatment of diseases within the fields of oncology, haematology, autoimmune and urology by providing both basic and speciality therapeutics. The company has offices globally, worldwide partner agreements in over 90 countries and approximately 1,200 employees. Trecondi® in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non-malignant diseases, and in paediatric patients older than one month with malignant diseases1. It is the only conditioning regimen to be NICE recommended2.
Phone: 07557 023607